Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.82 |
| ▸ | RAB9A | P51151 | 2/20 | 0.82 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.70 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.62 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.61 |
| ▸ | WNT1 | P04628 | 2/20 | 0.61 |
| ▸ | CHRNA7 | P36544 | 5/20 | 0.60 |
| ▸ | HTR3A | P46098 | 2/20 | 0.60 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.58 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.56 |
| ▸ | CDK2 | P24941 | 1/20 | 0.56 |
| ▸ | FLT3 | P36888 | 1/20 | 0.56 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.56 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.55 |
| ▸ | CNR1 | P21554 | 1/20 | 0.54 |
| ▸ | CNR2 | P34972 | 1/20 | 0.54 |
| ▸ | IDO1 | P14902 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26400414 | 0.89 | NPC1 (0.97) | NPC1RAB9ASMYD3USP30DYRK1A | |
| SCHEMBL30068489 | 0.88 | NPC1 (0.80) | NPC1RAB9ASMYD3USP30DYRK1A | |
| SCHEMBL7378117 | 0.88 | NPC1 (0.71) | NPC1RAB9ASMYD3USP30DYRK1A | |
| SCHEMBL21489892 | 0.86 | NPC1 (0.78) | NPC1RAB9ASMYD3USP30DYRK1A | |
| SCHEMBL19710468 | 0.86 | NPC1 (0.78) | NPC1RAB9ASMYD3USP30DYRK1A | |
| SCHEMBL8057262 | 0.86 | NPC1 (0.65) | NPC1RAB9ASMYD3USP30DYRK1A | |
| SCHEMBL29732688 | 0.84 | NPC1 (0.74) | NPC1RAB9ASMYD3USP30DYRK1A | |
| SCHEMBL6950689 | 0.84 | NPC1 (0.74) | NPC1RAB9ASMYD3USP30DYRK1A | |
| SCHEMBL2087351 | 0.83 | NPC1 (0.72) | NPC1RAB9ASMYD3USP30DYRK1A | |
| SCHEMBL23575893 | 0.82 | SMYD3 (1.00) | NPC1RAB9ASMYD3USP30DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060135589-A1 | 1h-Indazole-3-carboxamide compounds as cyclin dependent kinase (cdk) inhibitors | ASTEX TECHNOLOGY, INC. (GB) | 2006-06-22 | — | — | US | claimed |
| EP-1910340-B1 | INDAZOLECARBOXAMIDE DERIVATIVES AS 5HT4 RECEPTOR AGONISTS | PFIZER (US) | 2009-11-18 | — | — | EP | disclosed |
| US-20060135589-A1 | 1h-Indazole-3-carboxamide compounds as cyclin dependent kinase (cdk) inhibitors | ASTEX TECHNOLOGY, INC. (GB) | 2006-06-22 | — | — | US | disclosed |
| EP-1534685-A1 | 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS CYCLIN DEPENDENT KINASES (CDK) INHIBITORS | Astex Technology Limited (GB) | 2005-06-01 | — | — | EP | disclosed |
| WO-2005014554-A1 | 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS MAPKAP KINASE MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-02-17 | — | — | WO | disclosed |
| WO-2004014864-A1 | 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS CYCLIN DEPENDENT KINASES (CDK) INHIBITORS | ASTEX TECHNOLOGY LIMITED (GB) | 2004-02-19 | — | — | WO | disclosed |
| EP-0829474-B1 | INDAZOLE DERIVATIVES HAVING MONOCYCLIC AMINO GROUP | NISSHIN SEIFUN GROUP INC (JP) | 2003-04-09 | — | — | EP | disclosed |
| US-6096746-A | Indazole compound containing a monocyclic amine structure | NISSHIN FLOUR MILLING CO., LTD. (JP) | 2000-08-01 | — | — | US | disclosed |
| US-5945434-A | TREATMENT OF GASTROINTESTINAL DISORDERS | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1999-08-31 | — | — | US | disclosed |
| EP-0829474-A1 | INDAZOLE DERIVATIVES HAVING MONOCYCLIC AMINO GROUP | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1998-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135589-A1 | 1h-Indazole-3-carboxamide compounds as cyclin dependent kinase (cdk) inhibitors | CCNC, CDK1, CDK7 | NPC1 4580/4885RAB9A 3100/4885SMYD3 2131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.